The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: StanChart, AstraZeneca lift FTSE 100 into green

Fri, 28th Jul 2023 08:52

(Alliance News) - Stock prices in London opened higher on Friday, boosted by a mostly strong set of company earnings, while investors weighed recent central bank decisions.

The FTSE 100 index opened up 21.41 points, 0.3%, at 7,714.17. The FTSE 250 was down 90.04 points, 0.5%, at 19,183.33, and the AIM All-Share was down 1.13 points, 0.2%, at 768.16.

The Cboe UK 100 was up 0.1%, the Cboe UK 250 was down 0.5% at 16,860.93, and the Cboe Small Companies was up 0.1% at 13,816.04.

In European equities on Friday, the CAC 40 in Paris was down 0.4%, while the DAX 40 in Frankfurt was down 0.1%. French equities failed to get a boost from a stronger-than-expected gross domestic product print, and returned some of their gains from Thursday.

The French economy saw a surprisingly robust performance in the second quarter of this year, growing by 0.5% from the first quarter, the statistics office announced.

The figure was well above the INSEE statistics office's own forecast of 0.1% growth for April to June and the expectations of analysts. It was also ahead of the 0.2% quarter growth seen in the first quarter.

Meanwhile, stocks in the FTSE 100 were outperforming their continental counterparts.

Standard Chartered was the top performer, up 5.4%.

The Asia-focused bank launched a new USD1 billion share buyback programme, as it reported a 20% rise in profit in the first half of 2023 and raised its guidance for the full year.

Pretax profit in the six months that ended June 30 was USD3.32 billion, up 20% from USD2.77 billion a year before. Operating income increased by 11% to USD9.13 billion from USD8.23 billion, and StanChart also benefitted from a reduced credit impairment of USD161 million, down from USD263 million a year before.

StanChart declared a 6 cents per share ordinary interim dividend, up 50% from a year before.

NatWest's interim results received a more muted reception, however, with its shares rising 0.3%.

Fresh from scandal, the bank touted its "robust balance sheet, with a high-quality deposit base, high levels of liquidity and a well-diversified loan book". In the first half of 2023, total income rose to GBP7.73 billion from GBP6.22 billion a year before, as net interest income came in at GBP5.73 billion from GBP4.33 billion. Operating pretax profit climbed to GBP3.59 billion from GBP2.62 billion. It declared an interim dividend of 5.5 pence and intends to begin a buyback of up to GBP500 million in the second half, in addition to the GBP1.3 billion buyback completed in the second quarter.

The results come amid the dramatic fallout in the row sparked by Nigel Farage over the closure of his Coutts bank account, which culminated in the resignation of NatWest CEO Alison Rose and the boss of Coutts, which is owned by the banking group.

"The bank is in extremely good shape in virtually all of its key metrics," noted interactive investor's Richard Hunter.

AstraZeneca rose 3.4% as it said pretax profit surged to GBP4.35 billion in the first half 2023, from just USD800 million a year before. Revenue rose edged up to USD22.30 billion from USD22.16 billion. The company reported significantly lower cost of sales, down 41% to USD3.87 billion from USD6.51 billion.

"Each of our non-Covid-19 therapy areas saw double-digit revenue growth, with eight medicines delivering more than USD1 billion of revenue in the first half, demonstrating the strength of our business," said CEO Pascal Soriot.

In the FTSE 250, Vanquis Banking plunged 25%.

The lender swung to a pretax loss of GBP14.5 million in the first half, from a profit of GBP46.9 million the year before. Total income slipped to GBP237.1 million from GBP240.3 million.

Sterling was quoted at USD1.2782 early Friday, down from USD1.2865 at the London equities close on Thursday. The euro traded at USD1.0963, lower than USD1.0996.

In Asia on Friday, the Nikkei 225 index in Tokyo closed down 0.4%, having fallen as low as 2.4%. The yen strengthened following a policy adjustment from Japan's central bank.

The Bank of Japan said it will allow "greater flexibility" in controlling bond yields, as it raised its full-year inflation forecast to 2.5% from its previous estimate of 1.8%.

It said it would continue to allow 10-year JGB yields to "fluctuate in the range of around plus and minus 0.5 percentage points from the target level, while it will conduct yield curve control with greater flexibility regarding the upper and lower bounds of the range as references, not as rigid limits," the central bank said in a statement. The bank also kept its short-term interest rate target unchanged at minus 0.1%.

Against the yen, the dollar was quoted at JPY139.10, down versus JPY141.07.

In China, the Shanghai Composite closed up 1.8%, while the Hang Seng index in Hong Kong was up 1.4%. The S&P/ASX 200 in Sydney closed down 0.7%.

In the US on Thursday, Wall Street ended lower, with the Dow Jones Industrial Average down 0.7%, the S&P 500 down 0.6% and the Nasdaq Composite down 0.6%.

Equities had earlier made a bright start after figures showed the US economy grew by more than expected in the second quarter of 2023, according to the first estimate from the US Bureau of Economic Analysis.

Quarter-on-quarter gross domestic product in the US increased 2.4% on an annualised basis in the second quarter of the year. In the first quarter, real GDP increased 2.0%, showing that the US economy has gathered some momentum.

Investors will have a keen eye on the US personal consumption expenditures reading at 1330 BST, which contains the latest core personal consumption expenditures deflator - the Federal Reserve's preferred metric of inflation.

Friday's economic calendar also has a German GDP reading at 0900 BST and an inflation reading from the eurozone's largest economy at 1300 BST.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.